Marc Lajoie, Outpace Bio CEO
With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies
Seattle startup Outpace Bio, a Lyell Immunopharma spinout using AI to design proteins for solid tumor cell therapies, has raised a $144 million Series B …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.